Background: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Evidence suggests that Osimertinib plus chemotherapy may prolong the progression-free survival (PFS) in with EGFR-mu-tated metastatic NSCLC patients. Aim of Study: To assess the efficacy outcome of Osime-rtinib plus platinum-based chemotherapy in EGFR-mutated metastatic NSCLC patients. Patients and Methods: This is a retrospective analysis which included 21 patients with EGFR-mutated metastatic NSCLC, treated with combination therapy of osimertinib at 80 mg once daily plus gemcitabine at 1000mg/m2 on D1 & D8 and carboplatin at an area under the curve 5 given every three weeks for four cycles. Results: The median PFS for patients was 17 months (95% CI 13.5-20.5), while the median OR was 22 months (95% CI 15.9-28.1). The one year PFS was 64%, while the one year OS was 84%. The objective response rate was 76.2%. The com-monest adverse effects, (AEs) were hematologic toxicity. Conclusions: First-line treatment with osimertinib plus chemotherapy offered prolonged PFS in patients with EG-FR-mutated metastatic NSCLC.